ONTY: Oncothyreon shares have been well on the fly of late, setting a new 52-week high last week of $6.50.
Stimuvax trials are winding down right now, with results probable to start leaking out towards the end of the year, and if the trial for non-small cell lung cancer proves to have been a success - use Dendreon (DNDN) as example of how the share price could react.
If Stimuvax makes it to market, however, keep in mind that the company has a commercial partner - Europe's Merck KGaA - with whom ONTY will have to share revenue.
That's a minor glitch, since the current ONTY market cap of still under $300 million is still relatively low compared to the potential of having an approved cancer vaccine.
Has the recent ONTY rise been related to some positive press and analyst upgrades, or is it more due to ASCO exposure?
Will be worth keeping an eye on this one as the time to results release draws nearer, but it's likely that we'll see a pullback before the final 'release' pop occurs.
Disclosure: No position.
